Cargando…
Dual Roles of the Mineral Metabolism Disorders Biomarkers in Prevalent Hemodilysis Patients: In Renal Bone Disease and in Vascular Calcification
BACKGROUND: Vascular calcification (VC) is highly prevalent in dialysis (HD) patients, and its mechanism is multifactorial. Most likely that systemic or local inhibitory factor is overwhelmed by promoters of VC in these patients. VC increased arterial stiffness, and left ventricular hypertrophy. Thu...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sciendo
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411002/ https://www.ncbi.nlm.nih.gov/pubmed/30867641 http://dx.doi.org/10.2478/jomb-2018-0026 |
_version_ | 1783402329284804608 |
---|---|
author | Baralić, Marko Brković, Voin Stojanov, Vesna Stanković, Sanja Lalić, Nataša Đurić, Petar Đukanović, Ljubica Kašiković, Milorad Petrović, Milan Petrović, Marko Stošović, Milan Ležaić, Višnja |
author_facet | Baralić, Marko Brković, Voin Stojanov, Vesna Stanković, Sanja Lalić, Nataša Đurić, Petar Đukanović, Ljubica Kašiković, Milorad Petrović, Milan Petrović, Marko Stošović, Milan Ležaić, Višnja |
author_sort | Baralić, Marko |
collection | PubMed |
description | BACKGROUND: Vascular calcification (VC) is highly prevalent in dialysis (HD) patients, and its mechanism is multifactorial. Most likely that systemic or local inhibitory factor is overwhelmed by promoters of VC in these patients. VC increased arterial stiffness, and left ventricular hypertrophy. Thus, the present study aimed to investigate the association of VC and myocardial remodeling and to analyze their relationship with VC promoters (fibroblast growth factor 23-FGF23, Klotho, intact parathormon-iPTH, vitamin D) in 56 prevalent HD patients (median values: age 54 yrs, HD vintage 82 months). METHODS: Besides routine laboratory analyzes, serum levels of FGF 23, soluble Klotho, iPTH, 1,25-dihydroxyvitamin D3; pulse wave velocity (PWV); left ventricular (LV) mass by ultrasound; and VCs score by Adragao method were measured. RESULTS: VC was found in 60% and LV concentric or eccentric hypertrophy in 50% patients. Dialysis vintage (OR 1.025, 95%CI 1.007–1.044, p=0.006) FGF23 (OR 1.006, 95% CI 0.992–1.012, p=0.029) and serum magnesium (OR 0.000, 95%CI 0.000–0.214, p=0.04) were associated with VC. Changes in myocardial geometry was associated with male sex (beta=-0.273, 95% CI -23.967 1.513, p=0.027), iPTH (beta 0.029, 95%CI -0.059–0.001, p=0.027) and vitamin D treatment (beta 25.49, 95%CI 11.325–39.667, p=0.001). Also, patients with the more widespread VC had the highest LV remodeling categories. PWV was associated patient’s age, cholesterol, diastolic blood pressure, LV mass (positively) and serum calcium (negatively), indicating potential link with atherosclerotic risk. CONCLUSIONS: Despite to different risk factors for VC and myocardial remodeling, obtained results could indicate that risk factors intertwine in long-term treatment of HD patients and therefore careful and continuous correction of mineral metabolism disorders is undoubtedly of the utmost importance. |
format | Online Article Text |
id | pubmed-6411002 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Sciendo |
record_format | MEDLINE/PubMed |
spelling | pubmed-64110022019-03-13 Dual Roles of the Mineral Metabolism Disorders Biomarkers in Prevalent Hemodilysis Patients: In Renal Bone Disease and in Vascular Calcification Baralić, Marko Brković, Voin Stojanov, Vesna Stanković, Sanja Lalić, Nataša Đurić, Petar Đukanović, Ljubica Kašiković, Milorad Petrović, Milan Petrović, Marko Stošović, Milan Ležaić, Višnja J Med Biochem Original Paper BACKGROUND: Vascular calcification (VC) is highly prevalent in dialysis (HD) patients, and its mechanism is multifactorial. Most likely that systemic or local inhibitory factor is overwhelmed by promoters of VC in these patients. VC increased arterial stiffness, and left ventricular hypertrophy. Thus, the present study aimed to investigate the association of VC and myocardial remodeling and to analyze their relationship with VC promoters (fibroblast growth factor 23-FGF23, Klotho, intact parathormon-iPTH, vitamin D) in 56 prevalent HD patients (median values: age 54 yrs, HD vintage 82 months). METHODS: Besides routine laboratory analyzes, serum levels of FGF 23, soluble Klotho, iPTH, 1,25-dihydroxyvitamin D3; pulse wave velocity (PWV); left ventricular (LV) mass by ultrasound; and VCs score by Adragao method were measured. RESULTS: VC was found in 60% and LV concentric or eccentric hypertrophy in 50% patients. Dialysis vintage (OR 1.025, 95%CI 1.007–1.044, p=0.006) FGF23 (OR 1.006, 95% CI 0.992–1.012, p=0.029) and serum magnesium (OR 0.000, 95%CI 0.000–0.214, p=0.04) were associated with VC. Changes in myocardial geometry was associated with male sex (beta=-0.273, 95% CI -23.967 1.513, p=0.027), iPTH (beta 0.029, 95%CI -0.059–0.001, p=0.027) and vitamin D treatment (beta 25.49, 95%CI 11.325–39.667, p=0.001). Also, patients with the more widespread VC had the highest LV remodeling categories. PWV was associated patient’s age, cholesterol, diastolic blood pressure, LV mass (positively) and serum calcium (negatively), indicating potential link with atherosclerotic risk. CONCLUSIONS: Despite to different risk factors for VC and myocardial remodeling, obtained results could indicate that risk factors intertwine in long-term treatment of HD patients and therefore careful and continuous correction of mineral metabolism disorders is undoubtedly of the utmost importance. Sciendo 2019-03-03 /pmc/articles/PMC6411002/ /pubmed/30867641 http://dx.doi.org/10.2478/jomb-2018-0026 Text en © 2019 Marko Baralić, Voin Brković, Vesna Stojanov, Sanja Stanković, Nataša Lalić, Petar Đurić, Ljubica Đukanović, Milorad Kašiković, Milan Petrović, Marko Petrović, Milan Stošović, Višnja Ležaić, published by sciendo http://creativecommons.org/licenses/by-nc-nd/3.0 This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. |
spellingShingle | Original Paper Baralić, Marko Brković, Voin Stojanov, Vesna Stanković, Sanja Lalić, Nataša Đurić, Petar Đukanović, Ljubica Kašiković, Milorad Petrović, Milan Petrović, Marko Stošović, Milan Ležaić, Višnja Dual Roles of the Mineral Metabolism Disorders Biomarkers in Prevalent Hemodilysis Patients: In Renal Bone Disease and in Vascular Calcification |
title | Dual Roles of the Mineral Metabolism Disorders Biomarkers in Prevalent Hemodilysis Patients: In Renal Bone Disease and in Vascular Calcification |
title_full | Dual Roles of the Mineral Metabolism Disorders Biomarkers in Prevalent Hemodilysis Patients: In Renal Bone Disease and in Vascular Calcification |
title_fullStr | Dual Roles of the Mineral Metabolism Disorders Biomarkers in Prevalent Hemodilysis Patients: In Renal Bone Disease and in Vascular Calcification |
title_full_unstemmed | Dual Roles of the Mineral Metabolism Disorders Biomarkers in Prevalent Hemodilysis Patients: In Renal Bone Disease and in Vascular Calcification |
title_short | Dual Roles of the Mineral Metabolism Disorders Biomarkers in Prevalent Hemodilysis Patients: In Renal Bone Disease and in Vascular Calcification |
title_sort | dual roles of the mineral metabolism disorders biomarkers in prevalent hemodilysis patients: in renal bone disease and in vascular calcification |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411002/ https://www.ncbi.nlm.nih.gov/pubmed/30867641 http://dx.doi.org/10.2478/jomb-2018-0026 |
work_keys_str_mv | AT baralicmarko dualrolesofthemineralmetabolismdisordersbiomarkersinprevalenthemodilysispatientsinrenalbonediseaseandinvascularcalcification AT brkovicvoin dualrolesofthemineralmetabolismdisordersbiomarkersinprevalenthemodilysispatientsinrenalbonediseaseandinvascularcalcification AT stojanovvesna dualrolesofthemineralmetabolismdisordersbiomarkersinprevalenthemodilysispatientsinrenalbonediseaseandinvascularcalcification AT stankovicsanja dualrolesofthemineralmetabolismdisordersbiomarkersinprevalenthemodilysispatientsinrenalbonediseaseandinvascularcalcification AT lalicnatasa dualrolesofthemineralmetabolismdisordersbiomarkersinprevalenthemodilysispatientsinrenalbonediseaseandinvascularcalcification AT đuricpetar dualrolesofthemineralmetabolismdisordersbiomarkersinprevalenthemodilysispatientsinrenalbonediseaseandinvascularcalcification AT đukanovicljubica dualrolesofthemineralmetabolismdisordersbiomarkersinprevalenthemodilysispatientsinrenalbonediseaseandinvascularcalcification AT kasikovicmilorad dualrolesofthemineralmetabolismdisordersbiomarkersinprevalenthemodilysispatientsinrenalbonediseaseandinvascularcalcification AT petrovicmilan dualrolesofthemineralmetabolismdisordersbiomarkersinprevalenthemodilysispatientsinrenalbonediseaseandinvascularcalcification AT petrovicmarko dualrolesofthemineralmetabolismdisordersbiomarkersinprevalenthemodilysispatientsinrenalbonediseaseandinvascularcalcification AT stosovicmilan dualrolesofthemineralmetabolismdisordersbiomarkersinprevalenthemodilysispatientsinrenalbonediseaseandinvascularcalcification AT lezaicvisnja dualrolesofthemineralmetabolismdisordersbiomarkersinprevalenthemodilysispatientsinrenalbonediseaseandinvascularcalcification |